400 related articles for article (PubMed ID: 34496935)
1. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Park JA; Wang L; Cheung NV
J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
[TBL] [Abstract][Full Text] [Related]
2. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
[TBL] [Abstract][Full Text] [Related]
3. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
Hoseini SS; Guo H; Wu Z; Hatano MN; Cheung NV
Blood Adv; 2018 Jun; 2(11):1250-1258. PubMed ID: 29858209
[TBL] [Abstract][Full Text] [Related]
4. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
[TBL] [Abstract][Full Text] [Related]
5. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the
Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K
Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract.
Sinha P; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2013 Nov; 62(11):1663-73. PubMed ID: 23982485
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
[TBL] [Abstract][Full Text] [Related]
8. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
Srivastava MK; Zhu L; Harris-White M; Kar UK; Huang M; Johnson MF; Lee JM; Elashoff D; Strieter R; Dubinett S; Sharma S
PLoS One; 2012; 7(7):e40677. PubMed ID: 22815789
[TBL] [Abstract][Full Text] [Related]
9. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
[TBL] [Abstract][Full Text] [Related]
10. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
Wu Z; Cheung NV
Pharmacol Ther; 2018 Feb; 182():161-175. PubMed ID: 28834699
[TBL] [Abstract][Full Text] [Related]
11. Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
Zonneville J; Colligan S; Grant S; Miller A; Wallace P; Abrams SI; Bakin AV
Int J Cancer; 2020 Oct; 147(8):2279-2292. PubMed ID: 32452014
[TBL] [Abstract][Full Text] [Related]
12. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
Middelburg J; Sluijter M; Schaap G; Göynük B; Lloyd K; Ovcinnikovs V; Zom GG; Marijnissen RJ; Groeneveldt C; Griffioen L; Sandker GGW; Heskamp S; van der Burg SH; Arakelian T; Ossendorp F; Arens R; Schuurman J; Kemper K; van Hall T
Nat Commun; 2024 Jan; 15(1):48. PubMed ID: 38167722
[TBL] [Abstract][Full Text] [Related]
13. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
[TBL] [Abstract][Full Text] [Related]
15. Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors.
Fan J; Zhu J; Zhu H; Xu H
Crit Rev Oncol Hematol; 2024 Jun; 198():104362. PubMed ID: 38614267
[TBL] [Abstract][Full Text] [Related]
16. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis.
Steding CE; Wu ST; Zhang Y; Jeng MH; Elzey BD; Kao C
Immunology; 2011 Jun; 133(2):221-38. PubMed ID: 21453419
[TBL] [Abstract][Full Text] [Related]
17. Key players of immunosuppression in epithelial malignancies: Tumor-infiltrating myeloid cells and γδ T cells.
Tamuli B; Sharma S; Patkar M; Biswas S
Cancer Rep (Hoboken); 2024 May; 7(5):e2066. PubMed ID: 38703051
[TBL] [Abstract][Full Text] [Related]
18. Efficient carcinoma cell killing by activated polymorphonuclear neutrophils targeted with an Ep-CAMxCD64 (HEA125x197) bispecific antibody.
Schweizer C; Strauss G; Lindner M; Marmé A; Deo YM; Moldenhauer G
Cancer Immunol Immunother; 2002 Dec; 51(11-12):621-9. PubMed ID: 12439607
[TBL] [Abstract][Full Text] [Related]
19. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
Ajith A; Mamouni K; Horuzsko DD; Musa A; Dzutsev AK; Fang JR; Chadli A; Zhu X; Lebedyeva I; Trinchieri G; Horuzsko A
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37651197
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration.
Xu J; Luo Y; Yuan C; Han L; Wu Q; Xu L; Gao Y; Sun Y; Ma S; Tang G; Li S; Sun W; Gong Y; Xie C
Int J Biol Sci; 2020; 16(9):1563-1574. PubMed ID: 32226302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
